Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gopa Iyer

Showing results (111-120 of 132) with videos related to

Pageof 14
Sort By:
European Urology|April 27, 2025
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial CarcinomaCarissa E Chu, Ziyu Chen, Karissa Whiting, et al.
Cancer Discovery|August 7, 2014
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinomaEliezer M Van Allen, Kent W Mouw, Philip Kim, et al.
Nature Communications|April 26, 2020
Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenograftsKwanghee Kim, Wenhuo Hu, François Audenet, et al.
Advances in Anatomic Pathology|June 15, 2021
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial CancersEva Compérat, Mahul B Amin, Jonathan I Epstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2018
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder CancerGopa Iyer, Arjun V Balar, Matthew I Milowsky, et al.
European Urology|November 16, 2024
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial CarcinomaKwanghee Kim, Syed M Alam, Fengshen Kuo, et al.
European Urology|September 26, 2025
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded CohortViranda H Jayalath, Melissa Assel, Gopa Iyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial CarcinomaJonathan A Coleman, Wesley Yip, Nathan C Wong, et al.
Advances in Anatomic Pathology|June 15, 2021
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of NeoplasiaMahul B Amin, Eva Comperat, Jonathan I Epstein, et al.
JCO Precision Oncology|May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder CancerAndrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
Pageof 14

Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
European Urology|April 27, 2025
Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial CarcinomaCarissa E Chu, Ziyu Chen, Karissa Whiting, et al.
Cancer Discovery|August 7, 2014
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinomaEliezer M Van Allen, Kent W Mouw, Philip Kim, et al.
Nature Communications|April 26, 2020
Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenograftsKwanghee Kim, Wenhuo Hu, François Audenet, et al.
Advances in Anatomic Pathology|June 15, 2021
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial CancersEva Compérat, Mahul B Amin, Jonathan I Epstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2018
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder CancerGopa Iyer, Arjun V Balar, Matthew I Milowsky, et al.
European Urology|November 16, 2024
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial CarcinomaKwanghee Kim, Syed M Alam, Fengshen Kuo, et al.
European Urology|September 26, 2025
Neoadjuvant Chemotherapy for High-risk Localized Upper Tract Urothelial Carcinoma: Final Long-term Outcomes from a Phase 2 Clinical Trial and an Expanded CohortViranda H Jayalath, Melissa Assel, Gopa Iyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial CarcinomaJonathan A Coleman, Wesley Yip, Nathan C Wong, et al.
Advances in Anatomic Pathology|June 15, 2021
The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of NeoplasiaMahul B Amin, Eva Comperat, Jonathan I Epstein, et al.
JCO Precision Oncology|May 1, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder CancerAndrew T Lenis, Karissa Whiting, Vignesh Ravichandran, et al.
Pageof 14